Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (2143)	6/20/2017 12:43:07 PM
From: Miljenko Zuanic	Respond to of 3559

yan mentioned several time in last two Q-cc. Everyone knows, but pretend "blind"! On another note, IF Roche is going against Geographic atrophy, associated with MD (wet and dry), with complement inhibitor, why is REGN silent???? What are they doing????

To: Felix B who wrote (2143)	6/20/2017 3:46:14 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

ARVO 2017: arvo.org P# A0087.....overal, ~50% pts were on > or = Q12W, second year of View1/2, 40-50% were on Q12W: <<Conclusions: A numerically higher proportion of patients treated with IAI received injections at =q12 week intervals compared to ranibizumab from week 52 to 96. Visual acuity gains achieved at week 52 were largely maintained through week 96 in both subgroups. These data indicate that many patients maintained their visual and anatomic improvements with dosing at =q12-week intervals following fixed dosing during the first year>> while here is mentioned only 30% (which is wrong, IMO):https://seekingalpha.com/article/4082631-brolucizumab-provides-comfort-novartis Trial Protocol Criteria to hold Q12W regimen may be different between this two drug trials???